# A Safety and Dose-finding Study of JNJ-26481585 for Patients With Advanced Solid Malignancies and Lymphoma.

> **NCT00677105** · PHASE1 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 92 (actual)

## Conditions studied

- Lymphoma
- Neoplasms

## Interventions

- **DRUG:** JNJ-26481585

## Key facts

- **NCT ID:** NCT00677105
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2012-09-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00677105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00677105, "A Safety and Dose-finding Study of JNJ-26481585 for Patients With Advanced Solid Malignancies and Lymphoma.". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00677105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*